Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Open in API
Filings indexed 950 across all filing types
Latest filing 2020-12-30 Regulatory Filings
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate developments. The text mentions a letter to shareholders discussing recent corporate developments, furnished as an exhibit. There is no detailed financial data or comprehensive report content such as an Annual Report (10-K) or Interim Report (IR). The document is not a transcript, proxy, or earnings release. It is a regulatory filing to inform the market of a corporate event, consistent with the definition of Regulatory Filings (RNS). The document length (7419 characters) and content confirm it is a standalone 8-K filing, not a full report or presentation. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-12-30 English
SC 13G
Major Shareholding Notification
2020-11-24 English
10-Q
Interim / Quarterly Report Q3 2020
2020-10-29 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or updates between periodic filings. The text specifically mentions the company issued a press release announcing financial results for the quarter ended September 30, 2020, and a business update. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length is 3729 characters, which is relatively short and consistent with a current report rather than a full quarterly or annual report. The document is not a transcript, proxy, or governance report. It is an announcement of financial results and business updates, typical of an 8-K filing. Therefore, the best classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain the full financial report itself.
2020-10-29 English
8-K/A
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, which is an amendment to a previous Form 8-K. It reports the final voting results of the company's 2020 Annual Meeting of Stockholders, specifically regarding the frequency of future Say-on-Pay votes. The document focuses on the submission of matters to a vote of security holders and the company's decision based on that vote. There is no detailed financial data or comprehensive report content, but rather an official disclosure of voting results. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and it is not a report publication announcement or certification. Therefore, the correct classification is DVA with high confidence.
2020-10-23 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 1, 2020, by Protalix BioTherapeutics, Inc. It reports the entry into a material definitive agreement, specifically an ATM Equity Offering Sales Agreement for up to $30 million of common stock. The document includes details about the sales agreement, the use of proceeds, and references to exhibits such as the sales agreement and legal opinions. There are no financial statements or comprehensive financial data presented, only an announcement of a financing agreement. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories. The document length is 5656 characters, sufficient to contain substantive information about the financing event. Therefore, the appropriate classification is CAP with high confidence.
2020-10-01 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.